Bli medlem
Bli medlem

Du är här


Hamlet: Clinical Study Coordinator for the HAMLET Bladder Cancer Trial

Hamlet Pharma has signed an agreement concerning the clinical phase II
study of HAMLET and the therapeutic effects on bladder cancer.
Professor Marek Babjuk has agreed to serve as the clinical study
coordinator and his unit at the Charles University and the Motol
University Hospital in Prague will perform the study. Professor
Babjuk is chairman of the European bladder cancer society and has
extensive experience in conducting clinical trials in bladder cancer
and other urological indications. The center will participate in
study design, prepare ethical documentation and recruit the patients.
After completion of the study, he will evaluate the clinical outcome
of the study. Molecular end points will be evaluated at Lund
University. Finally, Professor Babjuk will sit on the scientific
advisory board, which is formed by Hamlet Pharma for this study.

For further information, please contact

Catharina Svanborg, Professor, Lunds Universitet, +46-709 42 65 49

Mats Persson, CEO of Hamlet Pharma, +46 705 17 67 57

About Hamlet Pharma
Hamlet Pharma AB owns and develops a new technology to kill cancer
cells without harming healthy tissues. The HAMLET technology is
focused around the HAMLET family of tumoricidal protein-lipid
complexes, formed by naturally occurring molecules from human milk
and extended to include recombinant variants of the natural
substance. HAMLET has validated therapeutic efficacy in clinical
studies and animal models, and in many different cellular models of
human cancer. HAMLET will now be developed further for Phase II
clinical trials, to verify the positive proof of concept studies.
Hamlet Pharma AB shares are listed at AktieTorget. HAMLET is an
abbreviation for Human Alpha-lactalbumin Made LEthal to Tumor cells.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.